ArticleAIDS research and therapy2025
The association of antiretroviral therapy type and duration of use with stroke in people living with HIV in Zambia.
Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Literature Review on HIV-Viruses · 2026Review
Corrections and comments
- Update of
Authors and funding
17 authors.
Funding
Abstract
backgroundPeople living with HIV (PLWH) are at increased risk of stroke due to many factors including possibly antiretroviral therapy (ART) use. We sought to evaluate the association between ART type and duration of use with stroke in PLWH.
methodsWe conducted a prospective exploratory case-control study at the University Teaching Hospital in Lusaka, Zambia between March 2022 and October 2024 in adult (≥ 18 years) PLWH comparing those with stroke (cases) and without (controls) matched (1:2) for age, sex and race. Standardized data collection instruments were used to collect clinical, laboratory and imaging information. This information was compared between the cases and controls using Chi-square, t-tests, Mann-Whitney U-test (not normally distributed) and multivariable conditional logistic regression analyses with subgroup analysis by ART duration done for the cases.
resultsWe analyzed results for 205 cases and 410 controls. Compared to controls, cases were more likely to have hypertension (71% vs. 18%, p = 0.001), lower CD4 counts [293(163-592) cells/µl vs. 533 (376-688) cells/µl, p = 0.0001] and to be on second line ART (23% vs. 4%, p = 0.001). Hypertension (aOR 19.7, 95% CI 3.1-126.4, p = 0.002) and Tenofovir Disoproxil Fumarate (TDF) use (aOR 85.3, 95% CI 5.3-1380.7, p = 0.002) were associated with increased odds of stroke, whereas Dolutegravir (aOR 0.03, 95% CI 0.001-0.58, p = 0.02) and alcohol use (aOR 0.24, 95% CI 0.06-0.95) were associated with reduced odds of stroke. The majority of stroke patients on long-term ART were using Dolutegravir (80% vs. 35%, p = 0.001) and TDF (72% vs. 42%, p = 0.01).
conclusionIn PLWH, TDF associates with higher odds of stroke. Although Dolutegravir associates with reduced odds of stroke, stroke patients on long-term ART are more likely to be on it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.